Targeting triglycerides as a vascular risk factor is justified because of the role of triglyceride-rich lipoproteins in atherogenesis. This review examines recent evidence connecting triglycerides with cardiovascular disease (CVD) in the context of advances in insights concerning the pathophysiology, population burden and prognostic impact of fasting versus nonfasting values.
Introduction
The role of triglycerides in promoting cardiovascular disease (CVD) is still debated more than 60 years after a relationship was first postulated [1] . Recent data focusing on the potential importance of nonfasting triglyceride levels seem to settle this debate by establishing a consistent strong relation of triglycerides with CVD risk. In this review, we discuss the changing epidemiology of triglycerides in the community, summarize recent reports that underscore the importance of nonfasting values and highlight the complexity in making causal inferences based on the associations noted given the interdependence of lipid particles.
New insights into the role of triglycerides in atherogenesis
It is necessary to contemplate triglycerides as 'triglyceride-rich lipoproteins' (commonly referred to as 'TRLs') to emphasize the concept that the metabolism and turnover of triglycerides in the circulation may be as much (or more) a function of the composition of the other lipid and protein components of these particles as the fatty acid composition and concentrations of triglycerides per se [2, 3 ] . Clinically, the two main components of TRLs are the very-low-density lipoproteins (VLDL) and chylomicrons. As VLDLs result from hepatic synthesis and chylomicrons are postprandially produced by the gut, high triglyceride levels are thought of as having an endogenous basis (increased hepatic synthesis) or an exogenous origin (dietary) or both. Regardless of the origin of TRLs, the action of lipoprotein lipase in the capillary beds of the adipose tissue and muscles generates intermediate-density lipoproteins from VLDL or chylomicron remnants [3 ] .
Remnant TRL levels can be very high in dyslipidemic conditions characterized by high triglyceride levels but are ordinarily also present in the normal postprandial state. They are normally 'cleared' by the liver, but in persons with CVD TRLs remain increased in the circulation beyond the usual 4-8 h [4] . This failure to catabolize TRLs efficiently appears to be linked to accelerated atherogenesis as TRLs appear to be pro-inflammatory, cause endothelial dysfunction [5] , upregulate expression of endothelial adhesion molecules and promote macrophage chemotaxis. TRLs are especially prone to enter the arterial wall, where they are ingested by macrophages [analogous to oxidized lowdensity lipoprotein (LDL)], to then become foam cells [6] [7] [8] . Retention of these TRLs in the vascular wall also traps the more atherogenic small low-density lipoprotein cholesterol (LDL-C) particles [6, 9] .
The pathogenic effects of higher TRLs are intricately linked to those of higher levels of small dense LDL-C and lower concentration high-density lipoprotein cholesterol (HDL-C) that often coexist [10] . This is because higher TRLs are a key determinant of heterogeneity of LDL size; LDL particle size is strongly inversely related to the plasma triglyceride level [11] . This appears to result both from the derivation of small LDL particles from triglyceride-rich VLDL and from LDL-C remodeling involving neutral lipid exchange and lipolysis [12] . Smaller LDL particles appear less amenable to physiologic LDL clearance via the LDL receptor, which enhances their potential for avid binding to proteoglycans in the vascular wall. Furthermore, these small LDL particles appear to be more susceptible to oxidation, a property that further increases their atherogenicity [8] . Thus,plasma triglyceride is an indirect indicator of the relative proportion of circulat-ingsmallatherogenicLDL-Cparticlesandthus providesan indication of lipid particle size-related coronary risk. Persons with the same LDL-C can have a substantially differ-entCVDriskdependingontheirplasmatriglycerides,those with elevated triglyceride levels having a greater cardiovascular risk. The association of higher triglyceride levels with greater levels of small-dense LDL is reversed when high triglyceride levels are lowered with pharmacological treatment [13] .
TRLs are also intimately associated with cholesterol ester transfer protein (CETP)-mediated exchange of triglycerides with cholesterol esters in HDL-C particles. The triglyceride-enriched HDL particles are removed rapidly by hepatic lipase [14] . Thus, higher TRLs seem to accelerate the fractional catabolism of HDL ApoA-1 [15] , a phenomenon further enhanced by concomitant higher levels of Apo CIII that typically accompany higher triglyceride levels [16] . Hepatic steatosis that accompanies higher levels of TRL may mediate increased hepatic secretion of both Apo CIII and VLDL components [17, 18] . As plasma TRLs rise, clearance of apoAI and apoAII high-density lipoproteins is enhanced [19] . Smaller HDL particles are removed from the blood and catabolized more rapidly, limiting their efficiency in reverse cholesterol transport andconsequently diminishing their cardioprotective effect [20] .
These interrelationships among the lipids are most evident in the context of the metabolic syndrome, a construct that reflects presence of both obesity and insulin resistance. Persons with high triglyceride levels accompanied by reduced HDL-C can be presumed to have an atherogenic small LDL-C problem, particularly when accompanied by features of the metabolic syndrome. It remains to be precisely estimated to what extent insulin resistance is responsible for the risk factor clustering that often accompanies 'atherogenic dyslipidemia' and the high CVD risk it imposes. However, it seems likely that insulin resistance is responsible for a substantial proportion of the clustering and attendant elevated CVD risk observed in persons with increased triglyceride levels. Furthermore, high TRLs occur in a metabolic milieu additionally characterized by greater thrombogenicity, inflammation, and diminished fibrinolysis, all of which can further compound the elevated CVD risk. Additionally, several recent reports [21, 22] have highlighted the association of novel genetic loci with triglyceride levels in the community, emphasizing the need for additional studies to better elucidate the biological basis of high triglyceride states.
Burden of high triglyceride levels in the community
Two recent reports [23, 24] evaluated National Health and Nutrition Examination Surveys (NHANES) conducted in 1999-2002 and 2003-2004, assessing trends in mean lipid levels in the United States across these different cross-sectional surveys. The first report noted that mean triglycerides in adults (20-74 years) increased from 114 mg/dl in 1976-1980 to 122 mg/dl in 1999-2002 [23] . In the second report, mean triglycerides increased further to 129.5 mg/dl in 2003-2004 [24] . It was estimated that approximately 13% of the United States population (27 million people) have triglyceride levels exceeding 200 mg/dl; 7% have both high triglyceride and low HDL-C levels [24] . A more recent report from the National Lipid Association presented at the American Heart Association 2008 scientific sessions noted that mean US triglycerides continued to increase up to 2006 [25] . Compared to NHANES 1976-1980, data from surveys between 1999 and 2006 indicated that the proportion of individuals with isolated suboptimal triglycerides (<150 mg/dl) increased five-fold in people aged 60-74 years. About a third of adults have hypertriglyceridemia using this cutpoint (>150 mg/dl). This recent increase in mean triglycerides in the United States most likely reflects the increasing prevalence of obesity [25] .
Association with coronary heart disease risk: importance of nonfasting triglycerides Many epidemiological investigations have explored the connection between triglycerides and coronary heart disease (CHD) risk, but the association had not been well quantified until recently. Primary data from the Reykjavik Study and European Prospective Investigation of Cancer Norfolk Study were used to provide such information [26] and were incorporated into an updated meta-analysis of 27 additional prospective studies in western populations comprising 7 262 525 participants, including 10 158 CHD cases. One important observation from this report was that, in contrast to prior investigations, year-to-year consistency of individual triglyceride values was no different from those reported for blood pressure or for other lipids. In this meta-analysis, the risk factor-adjusted odds for developing CHD in patients with upper tertile triglycerides was 1.7 (relative to the lowest tertile), a risk ratio similar to that reported in Asian Pacific populations [27] . Furthermore, the data indicated an impact of triglycerides on CHD risk in men as well as women, and also, distinct from other studies, there was not much difference in the strength of the relation to CHD incidence in fasting versus nonfasting levels. In addition, the continuous graded influence of triglycerides on CHD incidence, as for other risk factors, extends down into what is regarded as the normal range with no indication of a critical value.
Another major recent study [28] focused on relating fasting triglycerides and changes in fasting triglycerides (over a 5-year period) to the incidence of CHD in 13 953 Israeli soldiers aged 26-45 years who were part of the Metabolic, lifestyle, and nutrition assessment in young adults (MELANY) Study. Over a follow-up of 10.5 years, men in the top triglyceride quintile had a four-fold adjusted hazard of developing CHD relative to those in the lowest quintile (P < 0.001 for trend across quintiles) in analyses adjusting for multiple confounders including HDL-C. Of note, men in whom triglyceride levels increased 5 years from baseline experienced an over three-fold greater risk of CHD relative to those in whom triglyceride levels continued to be low [28] .
Most prior population studies that initially noted associations between fasting plasma triglycerides and CVD risk found that after adjustment for other risk factors (particularly HDL-C) triglyceride was no longer an independent predictor [29] [30] [31] . Only a few studies found that triglyceride maintained its independent predictive power when potential confounders were taken into account [32] . It is difficult to distinguish the effects of triglycerides on CHD risk from that of low HDL-C, or from that of insulin resistance per se, both of which are strongly related to triglycerides. In addition, it is not clear whether it is appropriate to adjust for HDL-C, which is strongly inversely correlated with triglycerides and also biologically linked to insulin resistance in multivariable analyses. Austin [33] suggests possible underestimation of the triglyceride association with CHD because of the biological variation in its measurement and a strong inverse correlation between triglycerides and HDL-C, making multivariable assessment of its net effect difficult to interpret.
Traditionally, triglycerides have been measured in a fasting state because they are alleged to be too variable depending on when after a meal they are measured. In addition, before the availability of direct assays, LDL-C estimation requires fasting triglyceride values. It is important to note that the ubiquitous use of fasting triglycerides for CVD risk evaluation was not based on epidemiological evidence indicating that fasting specimens are superior. Quite to the contrary, investigators have postulated that humans are in a postprandial state most of the day and that atherosclerosis is a postprandial phenomenon [4, 34] .
As noted above, most epidemiologic investigations that relied upon fasting triglycerides concluded that they are only univariate predictors of vascular disease, the risk ratios becoming attenuated upon multivariable adjustment for HDL-C. Earlier meta-analyses of triglycerides as a CVD predictor universally limited their evaluation to studies using fasting triglycerides, which may have resulted in underestimation of the triglycerides' impact on vascular risk [35, 36] . Because postprandial lipids and their partially hydrolyzed chylomicron and VLDL remnants appear to promote accelerated atherogenesis by adversely affecting endothelial function and increasing numbers of atherogenic small LDL particles, thrombosis and inflammation, postprandial triglycerides could provide more relevant information on vascular risk than fasting levels.
Recent reports directly address the matter by comparing fasting with nonfasting triglycerides for CVD prediction [37] [38] [39] [40] [41] . The Women's Health Study involving 26 509 healthy American women, followed 11 years for CVD development and mortality, found that both fasting and nonfasting triglycerides were associated with future CVD after adjustments for age, blood pressure, smoking and hormone-replacement therapy [37] . Consistent with other studies in fasting patients, further adjustment for total cholesterol and HDL-C markedly weakened the association with CVD. However, nonfasting triglycerides maintained a strong independent relationship with future CVD in fully adjusted analyses. The hazard ratios increased sequentially with increasing tertiles of nonfasting triglycerides; the upper tertile conferring a significant two-fold increase in risk. Using triglycerides measured 4 h after a meal yielded the strongest (4.5-fold) relationship with CVD events [37] . In a follow-up report [40] , Mora et al. compared the predictive utilities of fasting versus nonfasting values for other lipids, noting that the predictive capability of HDL-C, total/HDL cholesterol ratio and apolipoprotein A-1 did not differ by fasting versus nonfasting state. Triglyceride levels predicted better when nonfasting values were used, whereas total cholesterol, LDL-C, and non-HDL cholesterol, apolipoprotein B-100 and B-100/A-1 ratio proved less helpful for CVD risk evaluation when nonfasting concentrations were used [40] .
Another long-term prospective cohort study involving 7587 women and 6394 men in Copenhagen also found that nonfasting triglycerides predicted vascular events after multivariable analysis [41] . The relationship was found in both sexes, and the highest risks were observed in persons with the highest postprandial triglycerides (5 mmol/l). A subsequent report [38] extended these observations to stroke events. A third report [39] , also based on the Copenhagen General Population Study, showed that postprandial lipid changes at any time are minimal compared with those in a fasting state and, indeed, found that, at all times through the day, the maximum increase in triglycerides averaged only 0.3 mmol/l or approximately 27 mg/dl with ordinary eating.
Nonfasting triglyceride has also been shown to be prospectively associated with increased CVD risk in Japanese men and women, after adjustment for both total cholesterol and HDL-C, and an Asia Pacific Cohort Studies Collaboration with data from 26 cohorts reported that nonfasting triglyceride was a stronger predictor of CVD than fasting triglycerides [27] .
Studies also attest to the fact that triglyceride levels measured after a standardized fat challenge predict the presence of CHD [4] . As in the case of fasting triglycerides, postprandial lipemia can be influenced by ethnicity, alcohol consumption and menopausal status, which must be considered in triglyceride evaluation. However, an outpatient oral triglyceride tolerance test has the disadvantage of increasing patient waiting time and effort and requires a direct measurement of LDL for comprehensive lipid evaluation.
Triglyceride as an indicator of insulin resistance
Increased triglyceride and decreased HDL-C levels are key metabolic abnormalities in insulin resistance states, including the metabolic syndrome and type 2 diabetes. The triglyceride/HDL cholesterol ratio has been advocated as a simple clinical indicator of insulin resistance that can serve as a convenient surrogate for evaluating the impact of insulin resistance on CHD incidence. The efficiency of blood lipids and their ratios (including total/HDL-C) for detection of insulin resistance and predicting its CHD hazard was recently investigated in 3014 Framingham Offspring Cohort participants [42 ] . The correlation between the triglycerides and the triglycer-ide/HDL ratio was 0.93, indicating that, for CHD risk assessment or evaluation of insulin resistance, measuring one is tantamount to using the other. The total/HDL-C ratio was also highly correlated with the triglyceride/HDL ratio (0.82). Insulin resistance (HOMA-IR) was similarly correlated with the triglyceride/HDL-C ratio (r ¼ 0.48), triglyceride itself (r ¼ 0.43) and the total/HDL-C ratio (r ¼ 0.43). Comparison of the multivariable-adjusted impact of the lipids and their ratios on CHD incidence indicated that the lipid ratios are somewhat more predictive and discriminative than each of their lipid components [42 ] . However, triglyceride (hazard ratio of 2.25, comparing the top tertile with the lowest) was almost as powerful a predictor of CHD as the triglyceride/HDL lipid ratio (hazard ratio 2.54) and discriminated cases equally well. The total/HDL-C ratio fared only slightly better (hazard ratio 2.78 versus 2.54). High triglyceride/HDL-C and total/ HDL-C ratios both indicated a degree of insulin resistance that warrants testing for impaired glucose tolerance or undetected diabetes. However, the impact of triglyceride or the triglyceride/HDL-C ratio on CHD incidence was only partially attributable to its association with insulin resistance. Surprisingly, CHD risk from insulin resistance appeared attributable as much to its association with an increased total/HDL-C ratio as to a high triglyceride/HDL ratio [42 ] .
Efficacy of treating elevated triglyceride levels
The current focus on LDL-C for assessing lipid risk and treatment seemingly needs broadening to accommodate the influence of other lipids. Given that the effect of triglycerides on CVD incidence extends incrementally down into its 'normal' range, the intensity of therapy to lower triglyceride levels, especially when only modestly elevated, should be determined taking into account an individual's global CVD risk status.
Use of non-HDL-C, as suggested by the Adult Treatment Panel (ATP) III [43] , is a reliable nonfasting marker that provides the sum of all apolipoprotein B-containing lipoproteins including TRLs. Non-HDL-C may be somewhat more effective for CVD prediction than LDL-C, especially when triglyceride levels are increased [44] . Accordingly, the National Cholesterol Education Program (NCEP) ATP III recommends non-HDL-C as a secondary target of therapy when triglyceride levels are at least 200 mg/dl, though a target level for triglyceride-lowering therapy is not specified [43] . Alternatively, apolipoprotein B itself might be measured, as it reflects the presence of all proatherogenic particles [45] .
At present, no clear evidence exists from intervention trials with a lipid-active drug that lowering triglyceride, independent of a change in other CVD risk factors, reduces major CVD events. However, recent post-hoc analysis of Pravastatin Atorvastatin and Infection ¼ Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) trial data [46] found that individuals treated with a high-dose statin who achieved a low triglyceride level on therapy had significantly fewer CVD events than those with a higher triglyceride level, even after adjusting for a lower LDL-C on therapy and other CVD risk factors. However, this finding does not necessarily imply that the extent of drug-induced triglyceride reduction accounts for reduction in CVD events.
Although use of postprandial triglycerides may have pathophysiologic support and demonstrated value for CVD prediction, no randomized trial data exist to demonstrate that triglyceride reduction per se lowers CVD incidence in the absence of other lipid effects.
Conclusion
High triglyceride level merits consideration as a prominent CVD risk factor because this often identifies candidates for CVD with insulin resistance, highly atherogenic small LDL remnant particles, lower values of HDL-C and other manifestations of the metabolic syndrome. The CVD risk of elevated LDL-C is enhanced by coexistent hypertriglyceridemia, and lowering both lipid fractions appears superior to reducing LDL-C alone. Recent epidemiological studies have underscored the associations of both fasting and nonfasting triglycerides with CVD risk.
